Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study.

Felicia Cosman Cyrus Cooper Yamei Wang Bruce H Mitlak S Varughese Setareh A Williams

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2022)

Following 18 months of treatment, abaloparatide was comparable to teriparatide for prevention of NVF and similar cardiovascular safety was demonstrated between cohorts.

Keyphrases

postmenopausal women
bone mineral density
body composition
health insurance
stem cells
replacement therapy